Literature DB >> 23074147

Cytotoxic action of Brazilian propolis in vitro on canine osteosarcoma cells.

N C Cinegaglia1, P R O Bersano, M C Búfalo, J M Sforcin.   

Abstract

Osteosarcoma (OSA) is a primary bone neoplasm frequently diagnosed in dogs. The biology of OSA in pet dogs is identical to that of pediatric patients, and it has been considered an excellent model in vivo to study human OSA. Since the individual response to chemotherapy is unpredictable and considering that propolis is a natural product with several biological properties, this work evaluated the cytotoxic action of propolis on canine OSA cells. The primary cell culture of canine OSA was obtained from the tumor of a dog with OSA. Cell viability was assessed after incubation with propolis, 70% ethanol (propolis solvent), and carboplatin after 6, 24, 48, and 72 h. Cell viability was analyzed by the crystal violet method. Data showed that canine OSA cells were sensitive to propolis in a dose- and time-dependent manner and had a distinct morphology compared to control. Its solvent (70% ethanol) had no effect on cell viability, suggesting that the cytotoxic action was exclusively due to propolis. Our propolis sample exerted a cytotoxic effect on canine OSA cells, and its introduction as a possible therapeutic agent in vivo could be investigated, providing a new contribution to OSA treatment.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Keywords:  chemotherapeutic agents; osteosarcoma; propolis

Mesh:

Substances:

Year:  2012        PMID: 23074147     DOI: 10.1002/ptr.4861

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  2 in total

1.  Effect of Propolis on Experimental Cutaneous Wound Healing in Dogs.

Authors:  Ashraf M Abu-Seida
Journal:  Vet Med Int       Date:  2015-12-13

2.  Anticancer effects of geopropolis produced by stingless bees on canine osteosarcoma cells in vitro.

Authors:  Naiara Costa Cinegaglia; Paulo Ricardo Oliveira Bersano; Maria José Abigail Mendes Araújo; Michelle Cristiane Búfalo; José Maurício Sforcin
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-18       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.